Literature DB >> 1535022

Gonadotrophin-releasing hormone agonist and laparoscopic myomectomy.

J B Dubuisson1, F Lecuru, H Foulot, L Mandelbrot, J Bouquet de la Jolinière, F X Aubriot.   

Abstract

The indications for operative laparoscopy have expanded greatly over the past decades, as its many advantages over laparotomy have been recognized. We report our techniques and short-term results concerning myomectomy by laparoscopy. From January 1, 1990 to October 1, 1991, 147 intraperitoneal myomectomies were performed in 70 patients: 46 of 70 were treated preoperatively with a depot gonadotrophin-releasing hormone agonist. No complications were observed. In selected cases, with the advantages of laparoscopic surgery, laparoscopic myomectomy appears to be a safe technique.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1535022

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  3 in total

Review 1.  Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders.

Authors:  G L Plosker; R N Brogden
Journal:  Drugs       Date:  1994-12       Impact factor: 9.546

Review 2.  Gonadotrophin-releasing hormone agonists. A guide to use and selection.

Authors:  M Filicori
Journal:  Drugs       Date:  1994-07       Impact factor: 9.546

3.  The role of laparoscopic-assisted myomectomy (LAM).

Authors:  D S Seidman; C H Nezhat; F Nezhat; C Nezhat
Journal:  JSLS       Date:  2001 Oct-Dec       Impact factor: 2.172

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.